Bevacizumab for the treatment of recurrent glioblastoma
Following on from information provided to NICE by the company, the appraisal of Glioblastoma – bevacizumab, was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- TA
- ID number:
- 80
- Referral date:
- 01 November 2008
- Topic area
- Cancer
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
- 2nd appraisal committee meeting:
- TBC
Project Team
- Communications manager:
- TBC
- Executive Lead:
- TBC
- Project manager:
- TBC
- Technical Lead:
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
16 November 2022 | Discontinued. Following on from information provided to NICE by the company, the appraisal of Glioblastoma – bevacizumab, was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
For further information on our processes and methods, please see our CHTE processes and methods manual